TABLE 1

HIV-1 NL4-3-derived peptides eluted from HIV-1-infected HLA-C*12:02-expressing cells

Eluted NL4-3 peptidePeptide nameLength (no. of residues)HIV proteinPositionsSynthesized peptide (based on worldwide HIV-1 clade B)
MSQVTNPATIMGag-MM1111Gag367–377MSQVTNSATIM
VTNPATIMGag-VM88Gag370–377VTNSATIM
FLGKIWPSHGag-FH99Gag433–441FLGKIWPSH
LGKIWPSHGag-LH88Gag434–441LGKIWPSH
FSVPLDKDFPol-FF99Pol271–279FSVPLDKDF
ILKEPVHGVYYPol-IY1111Pol464–474ILKEPVHGVYY
VSAGIRKVLPol-VL99Pol707–715VSAGIRKVL
VAVHVASGYPol-VY99Pol790–798VAVHVASGY
DAKLVITTYVif-DY99Vif61–69DAKLVITTY
MTKALGISYTat-MY99Tat39–47MTKALGISYc
VTIGKIGNMEnv-VM99Env318–326
RAIEAQQHLEnv-RL99Env557–566RAIEAQQHL
KAAVDLSHFNef-KF99Nef82–90KGALDLSHF
VARELHPEYNef-VY9a9Nef194–202MARELHPEY
VARELHPEYFNef-VF10b10Nef194–203
  • a Nef-VY9 was previously reported as immunodominant HLA-C*12:02-restricted epitope Nef-MY9 (52).

  • b Nef-VF10 included the Nef-VY9 epitope and was previously reported as Nef-MY10 (54).

  • c Tat-MY9 was synthesized based on the NL4-3 sequence.